Key Points {#d30e203}
==========

Targeted medication reviews of six key high-risk medicines can reduce iatrogenic disease in as little as 1 year.Pharmacists can deliver medication reviews safely and effectively.

Introduction {#Sec1}
============

Around 5 % of all hospital admissions are caused by adverse drug reactions, with a higher rate of up to 17 % in frail populations \[[@CR1]--[@CR4]\].

This is important in the context of polypharmacy. It is widely recognised that medication is the most common form of medical intervention: 80 % of people aged over 75 years take a prescription medicine \[[@CR5]\]. Furthermore, there is an increasing burden of people with multiple co-morbidities. Current disease management guidelines focus on treating each disease in isolation, which results in significant levels of polypharmacy, and such guidelines do not take into account the holistic management of a patient \[[@CR6]\]. Since work began on this study, a national polypharmacy guideline was published in Scotland to try to tackle inappropriate polypharmacy \[[@CR7]\].

A small group of medicines is frequently implicated in hospital admissions, termed in this study as 'high-risk medicines'. Medicines can have a higher risk of an adverse event because of three types of risk factor: the effect of the medicine itself, the result of combining two or more medicines, or patient-specific risk factors. Such high-risk medicines have been described by previous research \[[@CR8]\] and a recent systematic literature review listed 46 tools to identify high-risk medicines and inappropriate prescribing \[[@CR9]\]. In this study, the high-risk medicines were defined by the National Health Service (NHS) Highland Polypharmacy Guideline \[[@CR10]\], which was a precursor to the Scottish Polypharmacy Guidance \[[@CR7]\].

Therefore, this study was not about identifying the high-risk medicines that can cause adverse events. Instead, we hypothesised that by identifying all patients being prescribed known high-risk medicines and taking actions to minimise risk, the rate of iatrogenic disease associated with these medicines could be reduced.

The aim of our study was to identify a short list of high-risk medicines for which there is the greatest benefit to patients of targeted medication review. This short list could be used as a component of regular medication reviews in primary care by either pharmacists or GPs, with the aim of reducing iatrogenic disease and patient harm.

The value of medication review, including using a pharmacist to provide reviews, has been previously described \[[@CR11], [@CR12]\]. However, two large systematic reviews of 38 \[[@CR13]\] and 32 \[[@CR14]\] trials have found there is, at best, only weak evidence that pharmacist-led medication reviews are effective in reducing hospital admissions or drug-related morbidity and mortality. One of these reviews \[[@CR13]\] calls for more trials of primary care-based pharmacist-led interventions to decide whether or not this intervention is effective.

We believe our study is the first to take a systematic approach to identify all patients in a defined geographical area who take a high-risk medicine, take appropriate action and then follow up 1 year later.

Method {#Sec2}
======

Setting {#Sec3}
-------

NHS Highland is the largest geographical health board in the United Kingdom, covering approximately 32,500 km^2^ (12,500 miles^2^) and representing 41 % of the land mass of Scotland. The population, however, is only around 320,000 (6 % of the Scottish population). This research was conducted within the North area of NHS Highland; all 17 primary care medical practices were invited to participate.

Study Design {#Sec4}
------------

The study was a prospective cohort study.

High-Risk Medicines {#Sec5}
-------------------

High-risk medicines and high-risk medicine combinations were identified from the NHS Highland Polypharmacy Guidance \[[@CR10]\] and developed with reference to additional information on anticholinergic drugs \[[@CR15]\] and the STOPP/START tool (Screening Tool of Older Persons' Prescriptions/Screening Tool to Alert doctors to Right Treatment) \[[@CR16]\]. The medicines and medicine combinations searched for in the study are listed in Table [1](#Tab1){ref-type="table"}.Table 1High-risk medicines and medicine combinations included in this studyHigh-risk categoryMedicine detailsNSAID plusAngiotensin conversing enzyme inhibitor/angiotensin II receptor antagonist and diureticeGFR below 60 mL/minHeart failureWarfarinAge over 75 years and no PPI protectionWarfarin plusAntiplateletNSAIDMacrolideQuinoloneMetronidazoleAzole antifungalHeart failure plusGlitazoneNSAIDTricyclic antidepressantAged over 60 years and takingBenzodiazepines/hypnoticsTricyclic antidepressantsAntipsychotics (including prochlorperazine for nausea/vertigo)Sedating antihistaminesAnticholinergics (see list below)Antihypertensive plus diureticDigoxinAnticholinergics with a clinically significant effectAmitriptylineAmoxapineAtropineBenztropineChlorpheniramineChlorpromazineClemastineClomipramineClozapineDarifenacinDesipramineDicyclomineDiphenhydramineDoxepinFlavoxateHydroxyzineHyoscyamineImipramineMeclizineNortriptylineOrphenadrineOxybutyninParoxetinePerphenazineProcyclidinePromazinePromethazinePropenthelinePyrilamineScopolamineTolterodineTrifluoperazineTrihexyphenidylTrimipramine*eGFR* estimated glomerular filtration rate, *NSAID* non-steroidal anti-inflammatory drug, *PPI* proton pump inhibitor

Patient Identification {#Sec6}
----------------------

All patients prescribed one or more of the high-risk medicines on a repeat prescription were identified via a search of the practices' computerised prescribing system. There were no exclusions.

Medicines Review {#Sec7}
----------------

The medicines review protocol was developed by an expert team of two primary care pharmacists, two hospital pharmacists and a consultant physician specialising in care of the elderly. The reviews were undertaken at the medical practices by a senior clinical pharmacist between June 2012 and February 2013. The review process is illustrated in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Process for medicines review

All patients for whom a recommendation to alter a prescription was made were followed up 12 months later. This involved review of the medical notes by a team of primary care clinical pharmacists using a standard pharmaceutical resource \[[@CR17]\] to describe and categorise the outcomes as one of the following:Medicine stopped: no adverse consequences; adverse consequence; original medicine restarted; or alternative medicine started.Medicine amended: no adverse consequences; adverse consequence; original medicine restarted; or alternative medicine started.

For all patients where the GP continued the medicine unchanged despite the pharmacist recommendation, the medical notes were reviewed to determine any untoward medicine-related effects including adverse drug reactions, hospital admissions or other medicine-related morbidity. Preventability of these effects was determined by reference to standard reference sources by two independent pharmacists \[[@CR17]\]. These were categorised as one of the following:Medicine continued: no adverse consequences; adverse consequences; or later actions taken.

Data Analysis {#Sec8}
-------------

Data were recorded in a spreadsheet designed for the project by a team of primary care clinical pharmacists. Data were then analysed by the two authors working independently from each other and were cross-checked before recording the final outcomes.

A statistical analysis was undertaken using Fisher's exact test to assess whether following the pharmacist's recommendations altered the risk of having an adverse outcome related to a high-risk medicine. Fisher's exact test was calculated using a 2 × 2 contingency table using GraphPad software \[[@CR18]\]. Potential confounding factors in the decision to accept or reject the pharmacist's recommendations were not controlled for.

Governance {#Sec9}
----------

This study was deemed service evaluation and hence was exempt from NHS ethical and research and development reviews.

Results {#Sec10}
=======

Sixteen of the seventeen primary care medical practices agreed to take part, with the one remaining practice expressing interest but was unable to participate due to a shortage of physician resources. The demographics of the 16 practices are provided in Table [2](#Tab2){ref-type="table"}. The overall trend is of an older population (22 % aged over 65 years) living either in very remote small towns or very remote and rural small settlements.Table 2Demographics of the 16 primary care medical practicesPracticePractice populationPatients aged over 65 years (%)Urban/rural classification^a^Average deprivation quintile^b^1603018.31532572122.7653351230.27824285522.87835124823.40816762318.05527227518.4652880528.45839247927.35841030425.338211203525.508312120927.63831363623.90831453224.628315249029.728216164526.7583This table is based on Community Health Index data from 2012 and 2013, available from NHS Information Services Division Scotland^a^Urban/rural classification: Urban 1: large urban settlements of over 125,000 people. Urban 2: other urban settlements of 10,000--125,000 people. Urban 3: accessible small towns (settlements of 3000--10,000 people, within 30 min drive of a settlement of 10,000 or more). Urban 4: remote small towns (settlements of 3000--10,000 people, within 30--60 min drive of a settlement of 10,000 or more). Urban 5: very remote small towns (settlements of 3000--10,000 people, more than 60 min drive of a settlement of 10,000 or more). Urban 6: accessible rural (settlements of less than 3000 people within 30 min drive of a settlement of 10,000 or more). Urban 7: remote rural (settlements of less than 3000 people, within 30--60 min drive of a settlement of 10,000 or more). Urban 8: very remote rural (settlements of less than 3000 people, more than 60 min drive of a settlement of 10,000 or more)^b^Average quintile of deprivation from 1 = most deprived to 5 = least deprived

Of the combined practice populations of 38,399 patients, 9.5 % (3643) were prescribed one or more high-risk medicines. For the majority of these patients (87.4 %, 3184), the pharmacist deemed the medicine and monitoring to be appropriate, and that the benefits of continuing treatment outweighed the risks.

Recommendations to amend the prescription or deprescribe a high-risk medicine were made 459 times. Some of these recommendations involved one patient who took more than one high-risk medicine, therefore the evaluation is of 459 recommendations rather than 459 patients (21 patients had two recommendations, seven patients had three recommendations, the remainder had one recommendation). Of the 459 recommendations, 19 were for patients who were lost to follow up. Therefore, the final number of recommendations included in the study was 440. Of these 440 recommendations, 413 (94 %) were for patients aged over 60 years.

Of the 440 recommendations made, GPs accepted 214 recommendations and rejected 226, giving an average acceptance rate of 49 % (range 20--80 %, see Table [3](#Tab3){ref-type="table"}). If the three GP practices with low acceptance rates are excluded, the acceptance rate is 61 %. Reasons for rejecting recommendations were varied: in some cases it was due to patient-specific clinical factors such as a patient's reluctance to withdraw a hypnotic or patient willingness to accept the risks associated with a particular medicine combination. A pattern of lower acceptance rate (seen at three GP practices) may have been due to a lack of GP engagement with the study.Table 3Number of pharmacist recommendations and the GPs' acceptance rate of recommendations at each practicePractice numberNumber of pharmacist recommendationsPractice populationPercentage population with pharmacist recommendationPercentage acceptance rate of pharmacist recommendationsNumber of adverse consequences when recommendation rejected17160301.1825.35526857211.1966.1843145122.7328.57243228551.1262.50151712481.3658.82066276230.8158.06275622752.4619.6458178052.1176.47193024791.2153.3301003040.00112120351.0347.621121712091.4135.2901306360.001405320.00151524900.6060.001162016451.2280.000

The 440 recommendations were then followed up 1 year later. No patients were lost to follow up. The results are summarised in Table [4](#Tab4){ref-type="table"}. A detailed breakdown of the 440 recommendations is shown in Table [5](#Tab5){ref-type="table"}.Table 4Summary of the outcomes of 440 recommendations made by pharmacist for high-risk medicines to be stopped or amendedInitial reviewAfter 1 year214 recommendations accepted by GP128 medicines stopped76 % remained stopped with no adverse consequences\
12 % original medicine re-started\
12 % safer medicine re-started86 medicines amended69 % remained amended with no adverse consequences\
22 % original medicine re-started\
9 % safer medicine re-started226 recommendations rejected by GP66 % medicines continued with no adverse events\
24 % later action taken to reduce risk of an adverse event\
10 % an adverse event occurredTable 5Details of all 440 recommendations made by pharmacist for high-risk medicines to be stopped or amendedHigh-risk medicine or combinationAccepted recommendationPercentage acceptedRejected recommendationPercentage rejectedDeprescribedAmendedAged \>60 years plus anticholinergic9560.9939.1Aged \>60 years plus antihypertensive and diuretic2028.6571.4Aged \>60 years plus antipsychotic4145.5654.5Aged \>60 years plus antipsychotic and hypnotic1033.3266.7Aged \>60 years plus antipsychotic and tricyclic antidepressant and anticholinergic000.01100.0Aged \>60 years plus antipsychotic and benzodiazepine000.01100.0Aged \>60 years plus benzodiazepine and hypnotic0220.0880.0Aged \>60 years plus benzodiazepine and tricyclic antidepressant000.03100.0Aged \>60 years plus benzodiazepine1111.81588.2Aged \>60 years plus digoxin0857.1642.9Aged \>60 years plus diuretic and other antihypertensives0233.3466.7Aged \>60 years plus hypnotic41843.12956.9Aged \>60 years plus hypnotic and sedating antihistamine000.02100.0Aged \>60 years plus hypnotic and tricyclic antidepressant1140.0360.0Aged \>60 years plus sedating antihistamine1033.3266.7Aged \>60 years plus tricyclic antidepressant111643.53556.5Aged \>60 years plus tricyclic antidepressant and benzodiazepine000.02100.0Aged \>60 years plus tricyclic antidepressant and sedating antihistamine1033.3266.7Heart failure plus glitazone10100.000.0Heart failure plus NSAID10100.000.0Heart failure plus tricyclic antidepressant5160.0440.0Triple whammy combination (ACE/ARB + NSAID + diuretic)55556.14743.9NSAID plus aged \>75 years and no gastro-protection31575.0625.0NSAID plus aspirin10100.000.0NSAID plus eGFR \<60 mL/min11042.31557.7NSAID plus heart failure2160.0240.0NSAID plus warfarin2033.3466.7Warfarin plus another antiplatelet10168.8531.3Warfarin plus macrolide01100.000.0Other2855.6844.4Total1288648.622651.4*ACE inhibitor* angiotensin converting enzyme inhibitor, *ARB* angiotensin-II receptor blocker, *eGFR* estimated glomerular filtration rate, *NSAID* non-steroidal anti-inflammatory drug, *PPI* proton pump inhibitor

In 22 (10 %) of the 226 rejected recommendations, an adverse event occurred. The 22 events are shown in Table [6](#Tab6){ref-type="table"}. All but one of the events was the specific event that the pharmacist's recommendation related to. Three events resulted in hospital admission and 19 resulted in an additional GP consultation.Table 6Adverse events following rejection of pharmacist's recommendationsHigh-risk medicine(s)Pharmacist recommendationOutcomePharmacist preventable?Age \>60 + TCAStop/reduce TCAFall. Medication considered to be a factorYesAge \>60 + TCAStop/reduce TCAFall. Medication considered to be a factorYesWarfarin + antiplateletReview need for combinationGastric ulcerYesAge \>60 + TCAStop/reduce TCAConfusion attributed to TCAYesTriple whammyStop NSAIDHigh INR attributed to NSAIDYesAge \>60 + benzodiazepineStop/reduce benzodiazepineDay-time drowsiness and headache attributed to benzodiazepineYesAge \>60 + hypnoticStop/reduce hypnoticRoad traffic accident due to next-day drowsinessYesAge \>60 + TCAStop/reduce TCAFall attributed to TCA. Hospital admissionYesTriple whammyStop NSAIDReflux due to NSAIDYesAge \>60 + multiple antihypertensivesConsider reduction of antihypertensivesDecreased renal function requiring antihypertensive to be stoppedYesAge \>60 + multiple antihypertensivesConsider reduction of antihypertensivesLow blood pressureYesAge \>60 + multiple antihypertensivesConsider reduction of antihypertensivesFalls and low blood pressureYesAge \>60 + antipsychotic + TCA + anticholinergicsStop/reduce TCAFall. Medication considered to be a factor. Hospital admissionYesAge \>75 + PPI no gastroprotectionStart PPIGastrointestinal bleeding requiring NSAID to be stoppedYesAge \>60 + hypnotic +TCAStop/reduce hypnotic and TCAFall. Medication considered to be a factorYesAge \>60 + antipsychoticStop/reduce antipsychoticFall. Medication considered to be a factorYesTriple whammy and NSAID in reduced renal functionStop NSAIDGastrointestinal side effects requiring NSAID to be stoppedYesAge \>60 + benzodiazepine + TCAStop/reduce benzodiazepine and TCAFalls and confusion attributed to medicationYesAge \>60 + hypnoticStop/reduce hypnoticDrowsinessYesAge \>60 + hypnoticStop/reduce hypnoticFall. Medication considered to be a factor. Hospital admissionYesAge \>60 + multiple antihypertensivesConsider reduction of antihypertensivesFall. Medication considered to be a factorYesAge \>60 + multiple antihypertensivesConsider reduction of antihypertensivesOedema due to amlodipine requiring dose reductionNo*INR* international normalised ratio, *NSAID* non-steroidal anti-inflammatory drug, *PPI* proton pump inhibitor, *TCA* tricyclic antidepressant

In the group in which the pharmacist's recommendation was rejected and the original medicine was continued, later action was taken by the GP in 24 % of cases. In 95 % of these cases, the action was the same as had been recommended by the pharmacist and was taken to reduce the risk of an adverse event. The most frequent actions were to stop a non-steroidal anti-inflammatory drug (NSAID) or hypnotic, to reduce the dose of a hypnotic and to change to a safer NSAID.

In the group in which the pharmacist's recommendation was accepted and the original medicine was stopped or amended, the original medicine had to be re-started in 16 % of cases. These medicines are listed in Table [7](#Tab7){ref-type="table"}. The reason for medicines being re-started was identified from patients' medical records: a reason was stated in 30 out of 35 cases. For all 30, the original medicine was re-started at the patient's request due to a loss of symptomatic control without the medicine. Of these, 29 % were NSAIDs for pain; 29 % were hypnotics for insomnia and 23 % were tricyclic antidepressants frequently used in low doses at night only for anxiety/insomnia/pain symptoms. In no case was the need to re-start a medicine due to an adverse event. Although a loss of symptom control can be unpleasant or inconvenient for a patient, it is not considered to be an adverse event of equivalent importance to those listed in Table [6](#Tab6){ref-type="table"}.Table 7List of medicines which were later re-started following being stopped or amended in line with the pharmacist's adviceHigh-risk medicine combinationNumber of times original medicine re-startedAged \>60 years plus anticholinergic3Aged \>60 years plus antihypertensive and diuretic3Aged \>60 years plus antipsychotic1Aged \>60 years plus antipsychotic and hypnotic1 (hypnotic only)Aged \>60 years plus hypnotic9Aged \>60 years plus tricyclic antidepressant7Heart failure plus tricyclic antidepressant1NSAID plus ACE inhibitor/ARB and diuretic7NSAID plus eGFR \<60 mL/min2NSAID plus heart failure1Total35*ACE inhibitor* angiotensin converting enzyme inhibitor *ARB* angiotensin-II receptor blocker, *eGFR* estimated glomerular filtration rate, *NSAID* non-steroidal anti-inflammatory drug

A statistical analysis was undertaken using Fisher's exact test. Patients who were re-started on their original medicine were excluded from the analysis. Therefore, the following data was entered in Fisher's exact test: 179 accepted recommendations with no adverse outcomes; 226 rejected recommendations with 22 adverse outcomes. This study found that the risk of having an adverse outcome was significantly reduced when the pharmacist's recommendation to stop or amend a high-risk medicine was followed compared with continuing a high-risk medicine unchanged (*p* \< 0.001).

Discussion {#Sec11}
==========

The aim of this study was to identify the high-risk medicines for which a targeted medication review is most beneficial. Six high-risk medicine groups were identified, and therefore we recommend that regular review of these six groups would reduce patient harm. The six medicine groups are listed in Table [8](#Tab8){ref-type="table"}; we have included a suggested action, although such actions are at the discretion of the prescriber because individual patient factors should also be considered.Table 8Six key high-risk medicines to target in regular medication reviewsHigh-risk medicineSuggested actionTriple whammy combination (NSAID, diuretic, ACE inhibitor)Stop NSAIDNSAID + reduced renal functionStop NSAIDNSAID + age \>75 + no PPIStop NSAID or add PPIHypnotic/benzodiazepine + age \>60Reduce or stop hypnotic/ benzodiazepineTricyclic antidepressant + age \>60Reduce or stop tricyclic antidepressantAntipsychotic + age \>60Reduce or stop antipsychotic*NSAID* non-steroidal anti-inflammatory drug, *ACE inhibitor* angiotensin converting enzyme inhibitor, *PPI* proton pump inhibitor

This study also set out to determine if targeted medication reviews can be safely undertaken by a pharmacist. We have demonstrated that targeted medication reviews of high-risk medicines conducted by a pharmacist are both safe and effective. When the pharmacist's recommendations were accepted, no adverse events were observed. In contrast, when the pharmacist's recommendations were rejected, 22 preventable adverse events including three hospital admissions occurred. It is also likely that the pharmacist's recommendations triggered later actions by GPs: in the group in which the pharmacist's recommendation was initially rejected, the GP implemented the action at a later date in around 20 % of cases.

These findings support previous research which has described the value of pharmacist-conducted medication review \[[@CR11], [@CR12]\]. It also adds to the evidence base of primary care-based pharmacist-led medication reviews in reducing hospital admissions and drug-related morbidity, something called for by a previous systematic review \[[@CR13]\].

Delivering high-quality pharmaceutical care is central to pharmacy strategy in Scotland \[[@CR19]\]. It is hoped that as pharmaceutical care services develop, pharmacists in all settings will consider targeting medication reviews to the high-risk medicine groups identified in this study. However, such medication reviews need not be restricted to one profession. Medication review is a core component of the Quality and Outcomes Framework within the general medical services contract \[[@CR20]\], so GPs may find it useful to target the high-risk medicine groups identified in this study.

Informal feedback from GPs during the study revealed that historically not all GPs in the practices included in the study took a holistic view to medication review. One GP commented: "I didn't really see the value of this project until a triple whammy combination was pointed out to me. I realised I had never looked at the persons' medicines holistically before so hadn't considered the risk she was at". Therefore, this study has already helped to inform better medication review among participating GP practices.

A weakness of our study is that outcomes were only reviewed after 1 year: it is unlikely that all outcomes would be observed within 1 year, and therefore a longer follow-up period would be useful. Therefore, we plan to carry out further research on the 440 recommendations in our cohort after 5 years.

A further weakness of our study was that we did not control for potential confounding factors in our statistical analysis. Our study was a prospective study which took a real-life approach. There were many potential confounding factors in the decision to accept or reject the pharmacist's recommendations. The biggest confounder was the variability between GPs at the 16 practices in their clinical judgement on deciding whether or not to accept the pharmacist's recommendation (see Table [3](#Tab3){ref-type="table"}). Some GPs were less engaged in the study than others, perhaps due to time pressures or willingness to accept advice from a pharmacist. Controlling for this confounder was not possible without limiting the study to one GP practice, which would have resulted in the population size being too small. Further confounders include the patient being in an unstable condition (e.g. due to co-morbidity or life circumstances) so it being an inappropriate time to implement a change to medicines, GP knowledge of a patient's past acceptance of medicine changes, and GP knowledge of a patient's ability to cope with a change to medicines. Within our real-life study population, it was impossible to identify all the potential confounders. Therefore, we decided not to control for confounders. A future area for research would be to design a revised version of this study that did control for these confounders.

We do not believe there was any bias in the pharmacist's reviews and recommendations. Each recommendation stated the evidence base upon which it was made, therefore reducing the risk of bias.

Conclusion {#Sec12}
==========

This study demonstrated that medication reviews for high-risk medicines are safe and effective, and that pharmacists are effective at delivering medication reviews. It identified six high-risk medicines that could form the basis of targeted medication reviews in order to reduce iatrogenic disease.

Appendix 1: High-risk medicines pharmacist reporting tool {#Sec13}
=========================================================
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